Merus (MRUS) Osake Kurssi
Merus Kurssi
Liikevaihto on kasvanut 45,6 % vuodessa viimeisten 11 vuoden aikana 34,88 M USD:een. Merusn nettomarginaali on nyt −595,9 %, laskenut −285,6 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 98,94 USD, eli yli nykyhintaa 9,9 %. 23 analyytikosta 9 suosittaa ostoa — kokonaiskonsensus on Pidä.
Merus osakekurssi
Merus liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Merus -osakkeesta
The business model of Merus NV focuses on developing innovative bispecific antibody therapeutics to treat various types of cancer. By utilizing its proprietary technology platform, Merus aims to design and develop bispecific antibodies that can simultaneously target and bind to multiple cancer cell targets. This unique approach has the potential to enhance the efficacy and safety profile of cancer treatments. Merus collaborates with pharmaceutical companies to advance its pipeline candidates, while also retaining rights to develop and commercialize certain product candidates. Through its research and development efforts, Merus NV strives to provide groundbreaking solutions for patients suffering from cancer-related diseases.
Merus NV is primarily active in the biotechnology industry.
The main competitors of Merus NV in the market include biotechnology companies such as Regeneron Pharmaceuticals, Inc., Amgen Inc., Genmab A/S, and Roche Holding AG. These companies operate in similar therapeutic areas, developing innovative antibody-based therapeutics and immuno-oncology treatments, potentially competing with Merus NV's pipeline. It is important for investors and market participants to closely monitor the competitive landscape as it can impact Merus NV's market share, product development, and financial performance.
Merus NV is a biotechnology company based in the Netherlands. Founded in 2003, the company specializes in developing innovative bispecific antibody therapeutics for the treatment of cancer. Merus NV has a unique approach to target tumor cells directly while minimizing side effects. The company has a strong pipeline of candidates, including MCLA-128, MCLA-117, and MCLA-158, targeting various types of cancers. With collaborations and partnerships with renowned pharmaceutical companies, Merus NV aims to advance the field of antibody therapeutics and make a lasting impact on patient care. Throughout its history, Merus NV has achieved significant milestones in drug discovery and clinical development, positioning itself as a key player in the biotechnology industry.
Merus NV, a leading biotechnology company, has achieved several significant milestones. The company successfully initiated multiple clinical trials, including ongoing studies for its innovative bispecific antibody programs. Merus NV also secured strategic collaborations with renowned pharmaceutical companies, further validating its cutting-edge technology and expanding its market reach. In addition, Merus NV has received regulatory approvals for its investigational therapies, paving the way for potential commercialization. These achievements demonstrate the company's strong commitment to advancing its pipeline and driving growth. Merus NV's dedication to scientific excellence and continuous innovation positions it as a formidable player in the biotech industry.
Merus NV is primarily present in the Netherlands and the United States.
Merus NV represents values such as innovation, collaboration, and patient-centricity. With a commitment to advancing bispecific antibody therapeutics, Merus NV aims to improve patient outcomes and address unmet medical needs. The company's corporate philosophy is based on fostering scientific excellence and leveraging its core technologies to develop transformative medicines. Merus NV embraces a culture of integrity, diversity, and teamwork, driving its pursuit of novel solutions in the field of oncology. By integrating its unique approach with strategic partnerships, Merus NV strives to deliver breakthrough treatments for patients.
Analyytikot asettavat tällä hetkellä Merus-osakkeelle keskimääräisen tavoitehinnan 99,48 USD (mediaani: 98,94 USD), mikä merkitsee +10,5 % viimeisimpään hintaan verrattuna. Konsensus perustuu 23 analyytikkoarvioon.
23 analyytikkoa arvioi tällä hetkellä Merus-osaketta: 9 suosittaa ostoa, 14 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Merus-yhtiöltä 49,33 M USD liikevaihtoa ja −5,44 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Merus-osake noteerataan hintaan 79,36 EUR (90,00 USD).
Merus-osake (MRUS) on listattuna 3 pörssissä, muun muassa: NASDAQ (MRUS), Frankfurt (2GH.F), München (2GH.MU).
Merus NV is a biotechnology company specializing in the development of bispecific antibodies for the treatment of cancer. The company's business model is based on the research, development, and commercialization of novel therapies to combat cancer. Merus NV has three main business areas and develops products in each of these categories: therapeutic products, diagnostics, and research. The company's therapeutic products utilize bispecific antibodies (Biclonics®) that combine the properties of two different antibodies, resulting in greater specificity, higher efficacy, and reduced toxicity. Merus NV is building a pipeline of bispecific antibodies targeting a variety of cancer types. Currently, the company has three products in clinical development: MeMo, MCLA-128, and MCLA-117. Merus NV collaborates closely with renowned pharmaceutical companies such as Incyte and DSM Biomedical in the development of cancer immunotherapies. In the diagnostics product line, Merus NV offers a technology platform that enables the development of diagnostic tests for therapeutic products and supports biomarker research. The company is also involved in the development of antibody imaging tools, serving an important role in toxic analysis and biomarker-driven clinical studies. Finally, Merus NV's research department supports its own development activities as well as those of external parties through collaborations and alliances. In summary, Merus NV's business model is based on the development, commercialization, and marketing of bispecific antibodies to combat cancer. With innovative solutions and technologies in the field of diagnostic tests and therapy monitoring, the company has distinct competitive advantages and can meet the demands of customers and partners. Merus NV is a leading company in the field of bispecific antibody technology and offers a diverse product pipeline to meet the demanding requirements of the entire cancer market.
odotettu liikevaihto Merus on 49,33 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Merus on −374,11 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Merus:n hinta-voitto-suhde (P/E) on tällä hetkellä −16,56. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Merus-osakkeen arvostusta.
Merus:n hinta-myynti-suhde (P/S) on tällä hetkellä 125,58. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Merus-osakkeen arvostuskennuslukuna.
Merus:n Eulpool-laatuscore on 3/10.
Merus:n ISIN on NL0011606264. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Merus:n WKN on A2AKFX. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Merus:n ticker on MRUS. Tämä pörssinoteeraus käytetään Merus-osakkeiden kauppaan pörssissä.
Merus osake
Merus vertaisryhmä
Merus Ticker
Merus FIGI
Kaikki tunnusluvut ja syvällinen analyysi Merus:sta
Meidän osakeanalyysimme Merus-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Merus:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: